Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
as temozolomide and methylprednisolone, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Rituximab may help
chemotherapy kill more cancer cells by making cancer cells more sensitive to the drugs.
Giving rituximab together with temozolomide and methylprednisolone may be an effective
treatment for primary CNS non-Hodgkin's lymphoma.
PURPOSE: This phase II trial is studying how well giving rituximab together with temozolomide
and methylprednisolone works in treating patients with recurrent primary CNS non-Hodgkin's
lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
North American Brain Tumor Consortium Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins